ABSTRACT
Multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) comprise a large fraction of hematologic malignancies diagnosed each year. However, the co-occurrence of these conditions in the same patient is rare. CD19- and B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapies have been approved in recent years with promising responses. Here, we present a patient who presented following a bone marrow biopsy that revealed MM with 20% lambda-restricted plasma cells with no evidence of lymphoma involvement in the marrow. A subsequent lymph node biopsy of a right thigh mass was done and revealed DLBCL. The patient received CD19-targeted CAR T-cell therapy and has no detectable MM or DLBCL. To our knowledge, this is the first case report in the literature describing a patient with concomitant MM and DLBCL who received CD19-targeted CAR T-cell therapy.
ABSTRACT
BACKGROUND: Outpatient oncology nurses are responsible for symptom assessment/management and care coordination during telephone triage. Nursing telephone triage interventions can improve patient outcomes and clinical efficiency. Therefore, the lack of education and training in telephone triage can greatly impact patient care. OBJECTIVE: Using a prospective pretest/posttest design, we sought to determine if a telephone triage educational workshop would improve oncology nurses' knowledge, confidence, and skill over 12 weeks. INTERVENTION/METHODS: The educational intervention incorporated an online didactic lecture, group case scenario, and feedback on a virtual triage simulation. Evaluation was conducted before and after the intervention through an online, 13-item survey (knowledge and confidence) and simulation utilizing a 56-item checklist (skills). RESULTS: Thirteen oncology nurses were enrolled; 54% did not have telephone triage experience before this job. A total of 12 participants completed the workshop. From pretest to posttest, there was a median 1.0 out of 5.0 (interquartile range, 2.8) improvement in confidence (P = .008) and a 26.3% (interquartile range, 15.2) improvement in skills (P = .002). There was no difference in knowledge scores from pretest to posttest (P = .11). CONCLUSIONS: This workshop was associated with an improvement in oncology nurse confidence and skill, using telephone triage models. It benefits an existing process within the outpatient center and it highlights a new educational strategy that may optimize nursing practice and improve patient care and experience. IMPLICATIONS FOR PRACTICE: This workshop contributes to existing evidence of telephone triage models and nursing education. The findings can guide future research, nursing orientation, and educational activities within the field of nursing and telehealth.
Subject(s)
Nurses , Oncology Nursing , Clinical Competence , Humans , Oncology Nursing/education , Prospective Studies , Telephone , TriageABSTRACT
Abstract Chemotherapy-induced alopecia causes an important impact on cancer patients and its risk of persistence is currently a considerable issue in cancer survivors. Of the various interventions proposed for the prevention of chemotherapy-induced alopecia, scalp cooling has emerged as an effective and safe strategy. This paper aims to provide an overview on scalp cooling and chemotherapy-induced alopecia prevention.
Subject(s)
Humans , Breast Neoplasms/drug therapy , Hypothermia, Induced , Antineoplastic Agents/adverse effects , Scalp , Antineoplastic Combined Chemotherapy Protocols , Alopecia/chemically induced , Alopecia/prevention & controlABSTRACT
Cancer treatment-related skin toxicities are a frequent and distressing side effect of antineoplastic therapies, especially chemotherapy and targeted therapies. Skin toxicities associated with these therapies can include rashes, hand-foot skin reaction, hand-foot syndrome, and hair loss. These symptoms cause not only physical pain and discomfort but also psychological distress, and they can become a stigma of the patient's cancer diagnosis. Skin toxicities can cause treatment delays and even discontinuation, which affects clinical outcome. The prevention of toxicities and effective, early management can reduce the risk for distress and treatment delays.
Subject(s)
Antineoplastic Agents , Drug-Related Side Effects and Adverse Reactions , Neoplasms , Skin Diseases , Alopecia , Antineoplastic Agents/adverse effects , Humans , Neoplasms/drug therapy , SkinABSTRACT
BACKGROUND: Management of cancer treatment-related skin toxicities can minimize treatment disruptions and improve patient well-being. OBJECTIVES: This guideline aims to support patients and clinicians in decisions regarding management of cancer treatment-related skin toxicities. METHODS: A panel developed a guideline for management of cancer treatment-related skin toxicities using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) for certainty of evidence and the National Academies of Sciences, Engineering, and Medicine criteria for trustworthy guidelines. The Cochrane risk-of-bias tool assessed risk of bias. A quantitative or narrative synthesis of the evidence was completed. RESULTS: The panel issued seven conditional recommendations for epidermal growth factor receptor inhibitor rash, hand-foot skin reaction, hand-foot syndrome, and chemotherapy-induced alopecia. The panel suggested strategies for prevention and treatment for all toxicities except hand-foot syndrome, which only has a prevention recommendation. IMPLICATIONS FOR NURSING: Cancer treatment-related skin toxicities can significantly affect quality of life. Incorporation of these interventions into clinical care can improve patient outcomes. SUPPLEMENTARY MATERIAL CAN BE FOUND AT HTTPS: //onf.ons.org/supplementary-material-ons-guidelines-cancer-treatment-related-skin-toxicity.
Subject(s)
Neoplasms , Skin Diseases , Humans , Neoplasms/drug therapy , Quality of LifeABSTRACT
Chemotherapy-induced alopecia causes an important impact on cancer patients and its risk of persistence is currently a considerable issue in cancer survivors. Of the various interventions proposed for the prevention of chemotherapy-induced alopecia, scalp cooling has emerged as an effective and safe strategy. This paper aims to provide an overview on scalp cooling and chemotherapy-induced alopecia prevention.
Subject(s)
Antineoplastic Agents , Breast Neoplasms , Hypothermia, Induced , Alopecia/chemically induced , Alopecia/prevention & control , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols , Breast Neoplasms/drug therapy , Humans , ScalpABSTRACT
Charge nurses often act as the eyes and ears of the unit. They are leaders, clinical experts, educators, policy enforcers, and patient advocates. They ensure patients and caregivers receive high-quality, safe, and evidence-based care. With the shift in health care from the in-patient to outpatient setting, patients are becoming more acute and complex for staff nurses. Charge nurses are pivotal in the successful care and management of these patients. Unfortunately, charge nurses often receive minimal training and are placed in this role with inadequate preparation and support. This can lead to feelings of anxiety, stress, and dissatisfaction with their job. Providing nurses with structured education about this role can create a safer and more positive work environment. This article discusses the development, implementation, and evaluation of a charge nurse orientation program in the outpatient infusion setting. [J Contin Educ Nurs. 2019;50(11):517-521.].
Subject(s)
Ambulatory Care/standards , Inservice Training/standards , Nurse Administrators/standards , Nursing Staff, Hospital/standards , Adult , Female , Humans , Male , Middle Aged , United StatesSubject(s)
Antineoplastic Agents/adverse effects , Neoplasms/drug therapy , Photosensitivity Disorders/epidemiology , Antineoplastic Agents, Immunological/adverse effects , Clinical Trials as Topic , Humans , Incidence , Molecular Targeted Therapy , Nivolumab/adverse effects , Piperidines/adverse effects , Quinazolines/adverse effects , Risk Assessment , Vemurafenib/adverse effectsABSTRACT
BACKGROUND: Dermatologic conditions cause morbidity and mortality among hospitalized cancer patients. An improved understanding is critical for implementing clinical and research programs in inpatient oncodermatology. OBJECTIVE: To characterize inpatient dermatology consultations at a large comprehensive cancer center. METHODS: Retrospective database query of new admissions and medical record review of initial inpatient dermatology consultations comparing inpatients consulted and not consulted during January-December 2015. RESULTS: In total, 412 of 11,533 inpatients received 471 dermatology consultations (54% male, median age 59.5 years). Patients with hematologic cancers were 6 times more likely to receive dermatologic consultations compared with nonhematologic cancers (odds ratio 6.56, 95% confidence interval 5.35-8.05, P < .0001). Patients consulted by a dermatologist had a significantly longer length of stay than inpatients not consulted by dermatology (median 11 vs 5 days, P < .0001). Among the 645 dermatologic conditions diagnosed, the most common categories were inflammatory diseases, infections, and drug reactions; the most frequent conditions were contact dermatitis, herpes zoster, and chemotherapy-induced drug eruptions. LIMITATIONS: The study's retrospective nature and single-institution setting are potential limitations. CONCLUSION: Hematologic malignancies are a significant risk factor for dermatology inpatient consultations. A significantly longer length of stay was associated with dermatology consultations, suggesting high comorbidities in these patients. Increased dermatologic care of these inpatients might improve quality of life, dermatologic health, and ability to receive anticancer agents.
Subject(s)
Dermatitis/epidemiology , Dermatitis/etiology , Drug Eruptions/epidemiology , Hospitalization/statistics & numerical data , Neoplasms/complications , Referral and Consultation/statistics & numerical data , Adult , Age Distribution , Aged , Cancer Care Facilities , Cohort Studies , Databases, Factual , Dermatitis/pathology , Drug Eruptions/etiology , Female , Humans , Incidence , Inpatients/statistics & numerical data , Male , Middle Aged , Neoplasms/drug therapy , Neoplasms/pathology , New York City , Retrospective Studies , Risk Assessment , Sex Distribution , Staphylococcal Skin Infections/epidemiology , Staphylococcal Skin Infections/etiologyABSTRACT
OBJECTIVE: To review the emerging sub-specialty of oncodermatology and the role of oncodermatology nurses as facilitators of interprofessional collaboration between the oncology team and the dermatology team. DATA SOURCES: Journal articles indexed on the National Library of Medicine database. CONCLUSION: The complexity of cancer care with new cancer therapies and their associated dermatologic adverse events profiles benefit from a collaborative, interprofessional approach between dermatology and oncology in the care of the patient with cancer. IMPLICATIONS FOR NURSING PRACTICE: Oncodermatology nurses are in roles that can facilitate interprofessional collaboration, optimizing the care of patients with cancer.
Subject(s)
Antineoplastic Agents/toxicity , Antineoplastic Agents/therapeutic use , Dermatology/methods , Medical Oncology/methods , Neoplasms/drug therapy , Skin Diseases/etiology , Skin Diseases/therapy , Humans , Interprofessional Relations , Patient Care Team/organization & administration , Professional RoleABSTRACT
BACKGROUND: Immunotherapy, specifically the use of checkpoint inhibitors, offers patients with cancer an alternative to chemotherapy, targeting different pathways to destroy cancer cells. The side effects of immunotherapies, as well as their impact on normal tissue, need to be assessed and managed based on their mechanisms of action. OBJECTIVES: This article presents an overview of immune-related adverse events (AEs). â©. METHODS: Common immune-related toxicities, as well as rare and refractory toxicities, are reviewed. â©. FINDINGS: Immunotherapy treatment is an option for many patients with cancer, and nurses must understand the distinct side effect profile of these agents. Prompt identification and expert management are the cornerstones of success when dealing with immune-related AEs, and oncology nurses play a key role in improving patient care.
Subject(s)
Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Drug-Related Side Effects and Adverse Reactions/etiology , Drug-Related Side Effects and Adverse Reactions/nursing , Melanoma/immunology , Melanoma/nursing , Oncology Nursing/standards , Adult , Aged , Aged, 80 and over , Education, Nursing, Continuing , Female , Humans , Immunotherapy/adverse effects , Immunotherapy/nursing , Male , Melanoma/drug therapy , Middle Aged , Practice Guidelines as TopicABSTRACT
Cancer treatments usually have side effects of bone marrow depression, mucositis, hair loss, and gastrointestinal issues. Rarely do we think of skin side effects until patients have been treated successfully with epidermal growth factor receptor inhibitors (EGFRi). Those reactions include papulopustular rash, hair changes, radiation dermatitis enhancement, pruritus, mucositis, xerosis, fissures, and paronychia. This article discusses the common skin reactions seen when using EGFRi and presents an overview of skin as the largest and important organ of the body, including an overview of skin assessment, pathophysiology of the skin reactions, nursing care involved, and introduction to oncodermatology.
Subject(s)
Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Drug-Related Side Effects and Adverse Reactions/etiology , ErbB Receptors/adverse effects , ErbB Receptors/therapeutic use , Neoplasms/drug therapy , Skin Diseases/etiology , Drug-Related Side Effects and Adverse Reactions/nursing , Drug-Related Side Effects and Adverse Reactions/physiopathology , Humans , Skin Diseases/nursing , Skin Diseases/physiopathologyABSTRACT
Advanced care providers (ACPs) and nurses are fundamental players in the assessment and management of immunotherapy-related dermatologic adverse events (irdAE). Pembrolizumab, nivolumab, and ipilimumab are approved for unresectable or metastatic melanoma, metastatic non-small cell lung cancer (pembrolizumab and nivolumab), metastatic head and neck squamous cell carcinoma (pembrolizumab and nivolumab), advanced renal cell carcinoma, and Hodgkin lymphoma (nivolumab). Atezolizumab is approved for urothelial carcinoma. These agents function as immune checkpoint inhibitors, activating T-cell-mediated antitumor immune responses through the inhibition of the programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte antigen 4 (CTLA-4). Immune checkpoint inhibitors have been reported to cause irdAEs, including rash, pruritus, and vitiligo, requiring an interdisciplinary approach to avoid dose reduction or discontinuation of treatment and to maintain quality of life. Advanced care providers and nurses play a critical role in the attribution, grading, and management of these untoward events and must be knowledgeable about their pathophysiology, incidence, assessment, and clinical presentation.
ABSTRACT
INTRODUCTION: The use of scalp cooling for the prevention of chemotherapy-induced alopecia (CIA) is increasing. Cold caps are placed onto the hair-bearing areas of the scalp for varying time periods before, during, and after cytotoxic chemotherapy. Although not yet reported, improper application procedures could result in adverse events (AEs). At present, there are no evidence-based scalp cooling protocols, and there is no regulatory oversight of their use. OBJECTIVE: To report the occurrence of cold thermal injury (frostbite) on the scalp, following the use of cold caps for the prevention of CIA. MATERIALS AND METHODS: We identified four patients who developed cold thermal injuries on the scalp following the application of cold caps. Medical records were analyzed to retrieve the demographic and clinical characteristics. RESULTS: The cold thermal injuries in our patients were grade 1/2 in severity and improved with topical interventions and interruption of cold cap use, although grade 1 persistent alopecia ensued in 3 patients. The true incidence of such injuries in this setting, however, remains unknown. CONCLUSIONS: Cold thermal injuries are likely infrequent and preventable AEs that may result from improper device application procedures during cold cap use. Although these untoward events are usually mild to moderate in severity, the potential occurrence of long-term sequelae (e.g., permanent alopecia and scarring) or the need to discontinue cold cap use, are not known. Prospective studies are needed to further elucidate the risk and standardize healthcare delivery methods, and to improve patient/supportive/healthcare provider education.
Subject(s)
Alopecia/prevention & control , Antineoplastic Agents/adverse effects , Frostbite/epidemiology , Hypothermia, Induced/adverse effects , Alopecia/chemically induced , Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Female , Frostbite/etiology , Humans , Hypothermia, Induced/instrumentation , Incidence , Middle AgedABSTRACT
Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer durable disease control in several malignancies. In some patients, immune checkpoint mAbs cause cutaneous immune-related adverse events. Although the most commonly reported cutaneous toxicities are mild, a subset may persist despite therapy and can lead to severe or life-threatening toxicity. Autoimmune blistering disorders are not commonly associated with immune checkpoint mAb therapy. We report a case series of patients who developed bullous pemphigoid (BP), an autoimmune process classically attributed to pathologic autoantibody formation and complement deposition. Three patients were identified. Two patients developed BP while receiving the anti-PD-1 mAb nivolumab, and one while receiving the anti-PD-L1 mAb durvalumab. The clinicopathologic features of each patient and rash, and corresponding radiologic findings at the development of the rash and after its treatment, are described. Patients receiving an anti-PD-1/PD-L1 mAb may develop immune-related BP. This may be related to both T-cell- and B-cell-mediated responses. Referral to a dermatologist for accurate diagnosis and management is recommended. Cancer Immunol Res; 4(5); 383-9. ©2016 AACR.
Subject(s)
Antineoplastic Agents/adverse effects , B7-H1 Antigen/antagonists & inhibitors , Drug Eruptions/etiology , Pemphigoid, Bullous/chemically induced , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Aged , Aged, 80 and over , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Drug Eruptions/diagnosis , Drug Eruptions/pathology , Female , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/drug therapy , Male , Melanoma/drug therapy , Melanoma/secondary , Nivolumab , Pemphigoid, Bullous/diagnosis , Pemphigoid, Bullous/pathology , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained. OBJECTIVE: We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs. METHODS: The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models. RESULTS: The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P < .001). LIMITATIONS: The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions. CONCLUSION: Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment.
Subject(s)
Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Enzyme Inhibitors/adverse effects , Molecular Targeted Therapy/adverse effects , Neoplasms/drug therapy , Skin Diseases/chemically induced , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Antineoplastic Agents, Hormonal/adverse effects , Antineoplastic Agents, Hormonal/therapeutic use , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Enzyme Inhibitors/therapeutic use , Hormone Antagonists/adverse effects , Hormone Antagonists/therapeutic use , Humans , Incidence , Neoplasm Proteins/antagonists & inhibitors , Neoplasms/complications , Prospective Studies , Risk , Severity of Illness Index , Skin Diseases/epidemiology , Skin Diseases/prevention & controlABSTRACT
BACKGROUND: Treatment options for patients with advanced or metastatic medullary thyroid cancer (MTC) have, in recent years, expanded with the approval of two tyrosine kinase inhibitors (TKIs): vandetanib and cabozantinib. Other agents, including TKIs, are under clinical investigation for MTC. Although patients treated with TKIs are at risk of developing dermatologic adverse events (AE), these untoward events may be mitigated through AE-driven algorithms. SUMMARY: AE-driven algorithms combine effective nonpharmaceutical and pharmaceutical treatment modalities implemented by a multidisciplinary effort that incorporates nursing interventions, patient education, and referrals to pain-management specialists, podiatrists, and dermatologists, as appropriate. Effective AE prevention and management reduce the need for dose interruptions and modifications, allowing patients the opportunity to derive the maximal benefit from TKI therapy, while maintaining quality of life. CONCLUSIONS: Optimal use of targeted therapies in the treatment of MTC depends on careful patient selection, interdisciplinary communication, and patient education and encouragement to enhance compliance and safety, optimize consistent dosing, and maximize the use of effective therapies.